Jo PalmerPhillips - ELYM Old Chief Officer
| ELYMDelisted Stock | USD 3.09 0.06 1.90% |
Insider
Jo PalmerPhillips is Chief Officer of ELYM Old
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
ELYM Old Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. ELYM Old's management efficiency ratios could be used to measure how well ELYM Old manages its routine affairs as well as how well it operates its assets and liabilities.ELYM Old currently holds 349 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. ELYM Old has a current ratio of 17.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ELYM Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Guizhong Liu | Adagene | 54 | |
| Brian MD | Rezolute | 50 | |
| Erick MD | Acrivon Therapeutics, Common | 67 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| David Mack | Pmv Pharmaceuticals | 63 | |
| LLM JD | Rezolute | 63 | |
| Luis Borges | Century Therapeutics | 62 | |
| Caroline Godfrey | PepGen | N/A | |
| Casi DeYoung | Shattuck Labs | 54 | |
| Gregory Russotti | Century Therapeutics | 58 | |
| David MBA | Champions Oncology | 56 | |
| Joseph Zakrzewski | AN2 Therapeutics | 63 | |
| Peter MD | Acrivon Therapeutics, Common | 62 | |
| Dr MBA | MediciNova | 60 | |
| Qinghai Zhao | Adagene | 64 | |
| Jason CPA | MediciNova | 47 | |
| Alexander Zurcher | Molecular Partners AG | 50 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| MD MBA | Shattuck Labs | 66 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Anne Lesage | Pharvaris BV | 64 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
ELYM Old Leadership Team
Elected by the shareholders, the ELYM Old's board of directors comprises two types of representatives: ELYM Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ELYM. The board's role is to monitor ELYM Old's management team and ensure that shareholders' interests are well served. ELYM Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ELYM Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
ELYM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ELYM Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 23.84 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 0.99 X | |||
| EBITDA | (13.65 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in ELYM Stock
If you are still planning to invest in ELYM Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ELYM Old's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |